Prevalence and pattern of smoking in university students--perspective from Islamabad.

M. Shaikh,A. Kamal

2004-03-01

Abstract:

What problem does this paper attempt to address?

Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs

Lorenza Magagnoli,Paola Ciceri,Mario Cozzolino

DOI: https://doi.org/10.1080/13543784.2024.2369307

2024-06-21

Expert Opinion on Investigational Drugs

Abstract:Introduction Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). It begins as an adaptive increase in parathyroid hormone levels to prevent calcium and phosphate derangements. Over time, this condition becomes maladaptive and is associated with increased morbidity and mortality. Current therapies encompass phosphate-lowering strategies, vitamin D analogues, calcimimetics and parathyroidectomy. These approaches harbor inherent limitations, stimulating interest in the development of new drugs for SHPT to overcome these limitations and improve survival and quality of life among CKD patients.

pharmacology & pharmacy
Treatment of multiple myeloma with I-aminocyclopentanecarboxylic acid (NSC-1026).

M. Krant,D. M. Iszard,A. Abadi,R. Carey

1962-09-01

Abstract:
Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management

Elmukhtar Habas,Mohsen Eledrisi,Fahmi Khan,Abdel-Naser Y. Elzouki,Fahmi Y. Khan,Abdel-Naser Y Elzouki

DOI: https://doi.org/10.7759/cureus.16388

2021-07-14

Cureus

Abstract:Serum calcium concentration is the main determinant of parathyroid hormone (PTH) release. Defect in the activation of vitamin D in the kidneys due to chronic kidney disease (CKD) leads to hypocalcemia and hyperphosphatemia, resulting in a compensatory increase in parathyroid gland cellularity and parathyroid hormone production and causing secondary hyperparathyroidism (SHP). Correction and maintenance of normal serum calcium and phosphate are essential to preventing SHP, hungry bone disease, cardiovascular events, and anemia development. Understanding the pathophysiology of PTH and possible therapeutic agents can reduce the development and associated complications of SHP in patients with CKD. Medical interventions to control serum calcium, phosphate, and PTH such as vitamin D analogs, calcium receptor blockers, and parathyroidectomy are needed in some CKD patients. In this review, we discuss the pathophysiology, clinical presentation, and management of SHP in CKD patients.
Design and fabrication of prosthetic leaflet heart valves.

R. E. Clark,P. Gould,W. M. Swanson,J. Kardos,H. Karara,J. Skelton,G. Butterworth

DOI: https://doi.org/10.3109/10731197409118607

Biomaterials Medical Devices and Artificial Organs

Abstract:A fundamental approach to the design of a new trileaflet prosthetic heart valve has involved basic studies in anatomy and biomaterials and complex stress analyses of the normal human aortic valve. These data have provided the keystones for design.
Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

Sharon M. Moe,Tilman B. Drüeke

DOI: https://doi.org/10.1159/000073945

2003-01-01

American Journal of Nephrology

Abstract:Secondary hyperparathyroidism (HPT) is a common complication of chronic kidney disease (CKD) that can lead to clinically significant bone disease. Additional consequences of secondary HPT, such as soft-tissue and vascular calcification, cardiovascular disease, and calcific uremic arteriolopathy, may contribute to the increased risk of cardiovascular morbidity and mortality among CKD patients. Secondary HPT arises from disturbances in calcium, phosphorus, vitamin D and parathyroid hormone metabolism, which develop early in the course of CKD and become more prominent as kidney function declines. The standard therapies currently recommended to correct mineral metabolism and bone disease in these patients include calcium supplementation, dietary phosphorus restriction, phosphate-binding agents, and treatment with vitamin D sterols. However, such medications often have significant effects on the serum levels of calcium and phosphorus, which result in exacerbation of the disease and significant extraskeletal morbidity and mortality. Thus, there is a need to identify more effective treatment approaches. This review discusses the pathophysiology of secondary HPT, the challenges faced in the management of this disorder, and the impact of current treatment options on patients' risks of morbidity and mortality. In addition, the development of new, more physiologically relevant therapies, which may lead to successful management of secondary HPT, is reviewed.

urology & nephrology
Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease

Daniela Del Pilar Via Reque Cortes,Tilman B Drueke,Rosa Maria Affonso Moysés

DOI: https://doi.org/10.1007/s11914-024-00881-3

Abstract:Purpose of review: This review is a critical analysis of treatment results obtained in clinical trials conducted in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), hyperphosphatemia, or both. Recent findings: Patients with CKD have a high mortality rate. The disorder of mineral and bone metabolism (CKD-MBD), which is commonly present in these patients, is associated with adverse outcomes, including cardiovascular events and mortality. Clinical trials aimed at improving these outcomes by modifying CKD-MBD associated factors have most often resulted in disappointing results. The complexity of CKD-MBD, where many players are closely interconnected, might explain these negative findings. We first present an historical perspective of current knowledge in the field of CKD-MBD and then examine potential flaws of past and ongoing clinical trials targeting SHPT and hyperphosphatemia respectively in patients with CKD.
Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease

Wenjie Zhang,Hailiang Ren,Qianxiu Liao,Jian Wu

DOI: https://doi.org/10.1007/s00223-024-01187-3

2024-02-21

Calcified Tissue International

Abstract:The study addresses the challenge of treating secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients, focusing on the cost-effectiveness of surgical versus pharmacological interventions. Conducting a retrospective analysis on 152 CKD patients with SHPT at the Third People's Hospital of Chengdu, the study matched 80 patients into two groups: 40 undergoing parathyroidectomy with autotransplantation (PTX + AT) and 40 treated with calcimimetics. PTX + AT was more effective in alleviating symptoms, particularly bodily pain, and demonstrated greater cost-effectiveness over a long-term period compared to calcimimetics. This was especially significant in patients with PTH levels > 1800 pg/mL and hyperphosphatemia. Despite similar initial costs, PTX + AT led to a substantial decrease in expenses during the 2–5 years post-treatment period, PTX + AT results in an ICER of -RMB 26.71/QALY for the first post-treatment year and -RMB-111.9k/QALY for the 2–5 year period, indicating cost-effectiveness with reduced long-term costs. The study also found an increased economic burden in managing patients with hyperphosphatemia. Surgical intervention (PTX + AT) is advocated as the primary treatment strategy for severe SHPT in CKD patients, owing to its long-term economic and clinical advantages. The results underscore the need for a severity-based approach in treating SHPT.

endocrinology & metabolism
Severe secondary hyperparathyroidism in a chronic kidney disease patient treated with Radiofrequency ablation: One case report

Gulimire Muhetaer,Guangyi Liu,Ling Zhang,Hong Jiang

DOI: https://doi.org/10.3389/fmed.2022.876692

2022-07-22

Abstract:End-stage renal disease (ESRD) is a global health problem with a high incidence (1) and a steadily increasing prevalence (2). Secondary hyperparathyroidism (SHPT) is a common and serious complication of chronic renal failure (CRF) in dialysis patients (3). It is mainly manifested as parathyroid hyperplasia caused by abnormal calcium and phosphorus metabolism and active vitamin D resistance, resulting in excessive secretion of parathyroid hormone (PTH), which leads to complications such as bone deformity, osteoarthralgia, pruritus, ectopic calcification, and cardiovascular calcification in CKD patients, significantly reducing the quality of life in CKD patients (4, 5). In patients with chronic kidney disease, secondary parathyroid gland hyperplasia needs to be treated as early as possible (6). Currently, there are a variety of treatment options, including vitamin D receptor agonists, xenacax hydrochloride, parathyroidectomy and ablation techniques, etc. (7, 8). Medical treatment is the main choice among these treatments, but it is invalid in patients with severe hyperparathyroidism. So, parathyroidectomy is suggested to do in those patients (9). However, many dialysis patients who have severe cardiopulmonary dysfunction cannot tolerate the trauma caused by surgery as the concept of minimally invasive surgery has been gradually introduced into all fields of surgery and medical treatment. Traditional surgery is no longer the only option. Radiofrequency ablation has been widely applied due to its advantages of less trauma, simple operation, and good repeatability. It has been reported to achieve good effects in treating secondary hyperparathyroidism patients (8). This case reports that one severe secondary hyperparathyroidism patient gets good therapeutic results from parathyroid radiofrequency ablation.
Vitamin D Receptor Activator Selectivity in the Treatment of Secondary Hyperparathyroidism

Diego Brancaccio,Jürgen Bommer,Daniel Coyne

DOI: https://doi.org/10.2165/00003495-200767140-00002

2007-01-01

Drugs

Abstract:Secondary hyperparathyroidism (SHPT) is a common and serious consequence of chronic kidney disease (CKD). SHPT is a complex condition characterised by a decline in 1,25-dihydroxyvitamin D and consequent vitamin D receptor (VDR) activation, abnormalities in serum calcium and phosphorus levels, parathyroid gland hyperplasia, elevated parathyroid hormone (PTH) secretion, and systemic mineral and bone abnormalities. There are three classes of drugs used for treatment of SHPT: (i) nonselective VDR activators or agonists (VDRAs); (ii) selective VDRAs; and (iii) calcimimetics. The VDRAs act on the VDR, whereas the calcimimetics act on the calcium-sensing receptor. Calcimimetics are commonly used in conjunction with VDRA therapy. By virtue of the differences in their chemical structure, the nonselective and selective VDRAs differ in their effects on gene expression, and ultimately parathyroid gland, bone and intestine function. Medications in all three classes are effective in suppression of PTH; however, clinical studies show that calcimimetics are associated with an unfavourable tolerability profile and hypocalcaemia, whereas nonselective VDRAs, and to a lesser extent selective VDRAs, are associated with dose-limiting hypercalcaemia and hyperphosphataemia. Selective VDRAs also have minimal undesirable effects on calcium absorption in the intestine, and calcium and phosphorus mobilisation in the bone compared with nonselective VDRAs. Calcium load in patients with CKD can lead to vascular calcification, accelerated progression of cardiovascular disease and increased mortality. High serum phosphorus levels are also associated with adverse effects on cardiorenal function and survival. Recent evidence suggests that VDRAs are associated with a survival benefit in CKD patients, with a more favourable effect with selective VDRAs than nonselective VDRAs. Paricalcitol, a selective VDRA, is reported to exert specific effects on gene expression in various cell types that are involved in vascular calcification and the development of coronary artery disease. This article examines the molecular mechanisms that determine selectivity of VDRAs, and reviews the evidence for clinical efficacy, safety and survival associated with the three drug classes used for treatment of SHPT in CKD patients.

pharmacology & pharmacy,toxicology
RNA-sequence Reveals Differentially Expressed Genes Affecting the Secondary Hyperparathyroidism

Siyu Chen,Yang Chen,Bing Pan,Wei Zhao,Hong Jiang,Jianghua Chen,Ping Zhang

DOI: https://doi.org/10.21203/rs.3.rs-3567207/v1

2023-01-01

Abstract:Background/aim Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), the mechanisms of cell proliferation leading to which has not been fully understood in recent years. And this study investigated the potential genes of tissue proliferation in secondary hyperparathyroidism. Materials and methods RNA sequencing (RNA-Seq) analysis was conducted to explore the potentially related genes of SHPT. Patients with secondary hyperparathyroidism indicated for surgical parathyroidectomy in our institution were reviewed and the parathyroid glands were removed for RNA-Seq analysis to measure the differential changes of RNA expression. Furthermore, we validated the differential genes expression by quantitative real-time PCR (qRT-PCR) in tissue samples and enzyme-linked immunosorbent assay (ELISA) in the serum of patients with or without SHPT. Results Our study identified 24 DEGs by RNA-Seq, among which 16 were upregulated and 8 were downregulated. Through the qRT-PCR, we further found that U2AF1L5, LTBP2, RGN in the hyperplasia group were significantly downregulated and RAP1GAP2 was significantly upregulated compared to the control group. And only Serum U2AF1L5 concentrations in patients with SHPT were significantly higher than those in healthy controls (0.360.27ng/ml vs 0.150.07ng/ml, P<0.05) as ELISA showed. Conclusion The genes including LTBP2, RGN, RAP1GAP2 and U2AF1L5 differentially expressed in tissues and serum in patients with SHPT.
Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism

Zeli Xiang,Ming Wang,Changxiu Miao,Die Jin,Hongyue Wang

DOI: https://doi.org/10.3389/fphar.2022.1020858

IF: 5.6

2022-10-04

Frontiers in Pharmacology

Abstract:A common consequence of chronic renal disease is secondary hyperparathyroidism (SHPT) and is closely related to the mortality and morbidity of uremia patients. Secondary hyperparathyroidism (SHPT) is caused by excessive PTH production and release, as well as parathyroid enlargement. At present, the mechanism of cell proliferation in secondary hyperparathyroidism (SHPT) is not completely clear. Decreased expression of the vitamin D receptor (VDR) and calcium-sensing receptor (CaSR), and 1,25(OH)2D3 insufficiency all lead to a decrease in cell proliferation suppression, and activation of multiple pathways is also involved in cell proliferation in renal hyperparathyroidism. The interaction between the parathormone (PTH) and parathyroid hyperplasia and 1,25(OH)2D3 has received considerable attention. 1,25(OH)2D3 is commonly applied in the therapy of renal hyperparathyroidism. It regulates the production of parathormone (PTH) and parathyroid cell proliferation through transcription and post-transcription mechanisms. This article reviews the role of 1,25(OH)2D3 in parathyroid cells in secondary hyperparathyroidism and its current understanding and potential molecular mechanism.

pharmacology & pharmacy
Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure

Mario Cozzolino,Maurizio Gallieni,Diego Brancaccio,Teresa Arcidiacono,Giuseppe Bianchi,Giuseppe Vezzoli

Abstract:Chronic kidney disease (CKD) causes alterations in mineral metabolism inducing the development of secondary hyperparathyroidism (HPT) and renal osteodystrophy. Recently, it has been suggested that these alterations play an important role in determining extraskeletal calcification and thus cardiovascular morbidity and mortality among CKD patients. An impaired 1 alfa -hydroxylation of 25-hydroxycholecalciferol (25(OH)D3) to 1,25-dihydroxycholecalciferol (1,25(OH)2 D3) with decreased circulating 1,25(OH)2 D3 levels is commonly observed in patients with creatinine clearance below 70 ml/min. The reduction in 1,25(OH)2 D3 production triggers the up-regulation of parathyroid hormone (PTH) synthesis, through a decreased suppression on PTH gene transcription and a decreased intestinal calcium absorption. A reduced expression of vitamin D receptor (VDR) and a less efficient binding of the complex 1,25(OH)2 D3 -VDR to specific DNA segments account for the resistance to 1,25(OH)2 D3 in target cells. Thus, absolute and relative 1,25(OH)2 D3 deficiency is one of the causes of secondary HPT in patients with CKD, together with phosphate retention and skeletal resistance to PTH. Consistently with these pathophysiological mechanisms, the therapeutic use of 1,25(OH)2 D3 still represents a milestone for the treatment of secondary HPT and renal osteodystrophy, even though hypercalcemia and hyperphosphatemia are common adverse events and may increase the risk of cardiovascular calcifications. To reduce the impact of such adverse effects while retaining anti-PTH activity, 1,25(OH)2 D3 analogues with lower calcemic effects have been synthesized and are now available for clinical use.
The 120-S minute: using analysis of work activity to prevent psychological distress among elementary school teachers.

K. Messing,A. Seifert,E. Escalona

DOI: https://doi.org/10.1037/1076-8998.2.1.45

IF: 7.707

Journal of Occupational Health Psychology

Abstract:Primary school teachers in Québec suffer psychological distress, as shown by the Québec Health Survey (M. Gervais, 1993; Santè Québec, 1995). The authors applied and extended the French model (F. Guérin, A. Laville, F. Daniellou, J. Duraffourg, & A. Kerguelen, 1991) of analysis of work activity to observing classroom teaching (14 women in 10 classrooms for a total of 48 hr 24 min) to identify stressful elements. The authors observed a rapid sequence of actions, eye fixations of short duration, little physical or mental relaxation, multiple simultaneous activities, and uncomfortable temperature and humidity levels. Teachers use many strategies to teach, to create a learning environment, and to maintain attention in classrooms under adverse conditions. Examination of these strategies led to recommendations to improve relations between the teachers and their supervisors and to make the classroom an easier place to teach.
Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease

Yichao Wang,Jiaye Liu,Yiqiao Fang,Shengliang Zhou,Xueting Liu,Zhihui Li

DOI: https://doi.org/10.3389/fendo.2024.1400891

IF: 6.055

2024-06-21

Frontiers in Endocrinology

Abstract:Background: Chronic kidney disease (CKD)-related secondary hyperparathyroidism (SHPT) is associated with higher morbidity and death. The goal of this study was to mine the SHPT data already available to do a meta-analysis on the global prevalence of SHPT caused by CKD. Methods: Embase, Medline, Web of Science, Cochrane Central Databases, and Google Scholar were searched to identify studies on the prevalence of SHPT due to CKD from inception to November 2023. Pooled prevalence was calculated using the DerSimonian-Laird random effects model with a logit transformation. Results: Twenty-one eligible studies involving 110977 patients were included. Our results revealed that the estimated global prevalence of SHPT due to CKD was 49.5% (95% CI 30.20–68.18), regardless of the diagnostic criteria. For subgroup analysis, Southern Asia (84.36%, 95% CI 79.35–88.34) had a significantly higher SHPT prevalence than other geographic regions. SHPT due to CKD was most prevalent in China (85.14%, 95% CI 81.74–88.00). Conclusions: SHPT due to CKD is highly prevalent. This necessitates awareness and therapeutic approaches from primary care physicians, medical professionals, and health strategy authorities. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024514007.

endocrinology & metabolism
Coincidence or Causality: Parathyroid Carcinoma in Chronic Kidney Disease—Case Report and Literature Review

Stefana Catalina Bilha,Anca Matei,Dumitru D. Branisteanu,Laura Claudia Teodoriu,Ioana Hristov,Stefan Bilha,Letitia Leustean,Maria-Christina Ungureanu,Delia Gabriela Apostol Ciobanu,Cristina Preda,Cristian Velicescu

DOI: https://doi.org/10.3390/diagnostics14111127

IF: 3.6

2024-05-30

Diagnostics

Abstract:Parathyroid carcinoma (PC) associated with primary hyperparathyroidism (PHPT) has been well investigated in recent years. Data regarding PC evolution in secondary hyperparathyroidism (SHPT) due to chronic kidney disease (CKD) are, however, scarce. Most features that raise the suspicion of PC in PHPT are part of the usual SHPT evolution in CKD, mirroring the natural changes undergone by the parathyroid glands. Therefore, pre-surgically establishing the malignant or benign character of the lesions is cumbersome. We present two cases of PC in end-stage renal disease, one of which was bilateral, diagnosed after total parathyroidectomy in a high-volume parathyroid surgery center. A literature review of the data was also performed. A systematic search of the PubMed/MEDLINE database until January 2024 identified 42 cases of PC associated with SHPT. Understanding the PC features in CKD might improve associated bone and mineral disease management, and reduce the risk of metastasis, parathyromatosis, or recurrence. Irradiation, prolonged immunosuppression, long dialysis vintage, and genotype may predispose to the malignant transformation of chronically stimulated parathyroids. Despite postsurgical diagnosis, favorable outcomes occurred when distant metastases were absent, even without "en bloc" resection. Further research is warranted to delineate specific diagnostic and therapeutic approaches tailored to this particular patient subpopulation.

medicine, general & internal
Metabolomic profile of secondary hyperparathyroidism in patients with chronic kidney disease stages 3-5 not receiving dialysis

Lingling Gan,Lijun Wang,Wanyi Li,Yamei Zhang,Bei Xu

DOI: https://doi.org/10.3389/fendo.2024.1406690

2024-07-04

Abstract:Introduction: Secondary hyperparathyroidism (SHPT) is a common and serious complication of chronic kidney disease (CKD). Elucidating the metabolic characteristics of SHPT may provide a new theoretical basis for its prevention and treatment. This study aimed to perform a metabolomic analysis of SHPT in patients with CKD stages 3-5 not receiving dialysis. Methods: A total of 76 patients with CKD, 85 patients with CKD-SHPT, and 67 healthy controls were enrolled in this study. CKD was diagnosed according to the criteria specified in the Kidney Disease Improving Global Outcomes 2012 guidelines. SHPT was diagnosed by experienced clinicians according to the Renal Disease Outcomes Quality Initiative Clinical Practice Guidelines. Serum renal function markers and the lipid profile were analyzed. Untargeted ultra performance liquid chromatography-tandem mass spectrometry was used to analyze the serum metabolites of patients with CKD and SHPT. Multivariate analysis of the data was performed using principal component analysis and partial least square discriminant analysis. Serum differential metabolites were identified and further characterized using databases. Pathway enrichment analysis was performed using the Kyoto Encyclopedia of Genes and Genomes database. Correlations between differential metabolites and clinical parameters were determined using the Spearman correlation. Results: The serum metabolomic profiles of patients with CKD with and without SHPT differed significantly. Differential metabolites were mainly enriched in the top four Kyoto Encyclopedia of Genes and Genomes pathways: phenylalanine, tyrosine, and tryptophan biosynthesis; sphingolipid metabolism; glycerophospholipid metabolism; and phenylalanine metabolism. In total, 31 differential metabolites were identified; of these, L-tryptophan and (R)-(+)-1-phenylethylamine were decreased, while other amino acids and their derivatives, uremia toxins, carnitine, and lipids, were increased significantly in patients with SHPT compared to those without. The 14 lipid metabolites were positively correlated with levels of Urea, serum creatinine, cystatin C, and triglycerides and negatively correlated with the estimated glomerular filtration rate and levels of total and high- and low-density lipoprotein cholesterol. Discussion: Disturbed amino acid and lipid metabolism were more apparent in patients with SHPT than in those without. This metabolomic profile of SHPT may provide a therapeutic foundation for its future clinical management.
Persistent secondary hyperparathyroidism caused by parathyromatosis and supernumerary parathyroid glands in a patient on haemodialysis

Jun Yang,Jun Zhang,Ning-hu Liu,Hao Liu,Meng-jie Dong

DOI: https://doi.org/10.1186/s12882-020-01917-3

2020-01-01

BMC Nephrology

Abstract:Background Secondary hyperparathyroidism (SHPT) is a common high-risk factor for mortality in end-stage renal disease, and parathyromatosis and supernumerary parathyroid glands are very rare causes of persistent SHPT. Preoperative diagnosis and removal of all hyperplastic parathyroid glands are challenging. We report a rare case of persistent SHPT due to parathyromatosis and supernumerary parathyroid glands and successful management by multiple imaging modalities. Case presentation A 53-year-old Chinese woman on haemodialysis experienced discomfort due to itching and bone pain due to persistent SHPT after parathyroidectomy. The supernumerary parathyroid glands and parathyromatosis were detected by multiple imaging modalities, including 99m Tc-sestamibi ( 99m Tc-MIBI) scans, ultrasonography and four-dimensional computed tomography (4D-CT) and then excised; pathological confirmation was performed. During follow-up, her serum calcium and parathyroid hormone levels were stable in the appropriate ranges, and no complications arose. Conclusions Because of persistent SHPH after parathyroidectomy in patients with haemodialysis, multiple imaging modalities, including 99m Tc-MIBI scans, 4D-CT and ultrasonography, are helpful for detecting supernumerary parathyroid glands and parathyromatoses. Accurate preoperative localization of this rare lesion is important for management, enabling the removal of all affected parathyroid tissues.
ISSUES OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH THE EYES OF AN ANESTHESIOLOGIST. EXPERIENCE OF PERIOPERATIVE ANESTHESIOLOGICAL SUPPORT AND INTENSIVE THERAPY IN PARATHYROID SURGERY

А.І. Денисенко,В.І. Черній,Р.П. Ткаченко,A.I. Denysenko,V.I. Cherniy,R.P. Tkachenko

DOI: https://doi.org/10.31612/2616-4868.2(16).2021.01

2021-06-25

Клінічна та профілактична медицина

Abstract:Secondary hyperparathyroidism (SHPT) affects a majority of patients with chronic kidney disease (CKD) in the third and above stages with manifestations of chronic renal failure (CRF), especially in patients undergoing hemodialysis. Despite the temporary effects obtained from taking calcimimetics, there is no significant breakthrough in the treatment of SHPT, and most of the patients require parathyroid surgery (PTS). This review describes the main pathophysiological changes in SHPT, their correction, summarizes the indications for PTS, reflects preoperative preparation, anesthetic management, perioperative intensive care, and possible complications associated with SHPT and CRF. The experience of treating 214 patients with SHPT, 237 PTS (23 in connection with relapse of SHPT), algorithm of examination, preoperative preparation, anesthetic management and perioperative intensive care are presented. In the postoperative period, patients are at risk of severe hypocalcemia and hungry bone syndrome, which require careful monitoring and calcium replenishment.
Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means

Tilman B. Drüeke,Tilman B. Dr�eke

DOI: https://doi.org/10.1007/s00467-004-1745-0

2005-01-21

Pediatric Nephrology

Abstract:Currently available options for the treatment of hyperparathyroidism secondary to chronic renal failure do not allow the achievement of target values for plasma calcium, phosphorus, and parathyroid hormone in the majority of patients with chronic kidney disease (CKD) stage 5. This is particularly true for CKD patients who have been referred to nephrologists late in the course of their disease and in whom prevention has not been possible. The advent of a new class of therapeutic agents, the calcimimetics, will allow an easier control of already established parathyroid overfunction, as has been demonstrated in several phase II studies and one phase III study with cinacalcet. Future studies will show whether an earlier start of treatment in patients with CKD stage 2, 3, and 4 allows the prevention of secondary hyperparathyroidism. Since all available experience has been gathered in adult patients it is also necessary to test the efficacy and safety of the calcimimetics in children with CKD.

pediatrics,urology & nephrology
Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study

Wenqiang Qiu,Ge Zhou

DOI: https://doi.org/10.1186/s12893-023-02143-y

2023-08-12

Abstract:Purpose: Parathyroidectomy (PTX) is commonly performed as a treatment for secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease (ESRD). We aimed to evaluate the efficacy of PTX in patients with SHPT who underwent hemodialysis. Methods: This retrospective study analyzed the clinical treatment of 80 hemodialysis patients with SHPT who underwent either total PTX with forearm auto transplantation (TPTX + AT) or subtotal parathyroidectomy (SPTX). We compared the changes in biochemical indices before and after surgery as well as the attenuation of intact parathyroid hormone (iPTH) in the TPTX and SPTX groups. We also evaluated clinical symptoms and quality of life using the Visual Analog Scale (VAS) and the Short Form-36 Questionnaire (SF-36) before and at 3, 6, and 12 months after surgery. Results: Serum iPTH and serum phosphorus levels decreased significantly after surgery in 80 patients with SHPT (P < 0.05). Within one month of surgery, there was a difference in iPTH levels between the TPTX + AT and SPTH groups, but there was no difference over time. Patients experienced significant improvement in their clinical symptoms of restless leg syndrome, skin itching, bone pain, and joint pain at 1 week post operation (P < 0.001). Quality of life significantly improved after surgery, as assessed by SF-36 scores (P < 0.05). Hypocalcemia was the most common postoperative complication, occurring in 35% of patients. Within the first 12 months post surgery, 5 patients had a recurrence. Conclusion: PTX is effective in rapidly reducing iPTH levels, improving calcium and phosphorus metabolism disorders, and enhancing patients' quality of life by safely and effectively relieving clinical symptoms.

Prevalence and pattern of smoking in university students--perspective from Islamabad.

Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs

Treatment of multiple myeloma with I-aminocyclopentanecarboxylic acid (NSC-1026).

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management

Design and fabrication of prosthetic leaflet heart valves.

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

Persistent uncertainties in optimal treatment approaches of secondary hyperparathyroidism and hyperphosphatemia in patients with chronic kidney disease

Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease

Severe secondary hyperparathyroidism in a chronic kidney disease patient treated with Radiofrequency ablation: One case report

Vitamin D Receptor Activator Selectivity in the Treatment of Secondary Hyperparathyroidism

RNA-sequence Reveals Differentially Expressed Genes Affecting the Secondary Hyperparathyroidism

Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism

Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure

The 120-S minute: using analysis of work activity to prevent psychological distress among elementary school teachers.

Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease

Coincidence or Causality: Parathyroid Carcinoma in Chronic Kidney Disease—Case Report and Literature Review

Metabolomic profile of secondary hyperparathyroidism in patients with chronic kidney disease stages 3-5 not receiving dialysis

Persistent secondary hyperparathyroidism caused by parathyromatosis and supernumerary parathyroid glands in a patient on haemodialysis

ISSUES OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH THE EYES OF AN ANESTHESIOLOGIST. EXPERIENCE OF PERIOPERATIVE ANESTHESIOLOGICAL SUPPORT AND INTENSIVE THERAPY IN PARATHYROID SURGERY

Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means

Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study